| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011673480 |
| P356 | DOI | 10.1038/428486A |
| P3181 | OpenCitations bibliographic resource ID | 984676 |
| P698 | PubMed publication ID | 15057820 |
| P50 | author | Yuan-Tsong Chen | Q8933624 |
| P2093 | author name string | Hong-Shang Hong | |
| Hsin-Chun Ho | |||
| Jer-Yuarn Wu | |||
| Li-Cheng Yang | |||
| Mo-Song Hsih | |||
| Shuen-Iu Hung | |||
| Wen-Hung Chung | |||
| P2860 | cites work | Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis | Q34057610 |
| HLA DNA typing and transplantation | Q34241099 | ||
| Pharmacogenetics goes genomic | Q35590351 | ||
| The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification | Q40658443 | ||
| Toxic epidermal necrolysis in a burns centre: a 6-year review | Q41090828 | ||
| High Association of an HL-A Antigen, W27, with Ankylosing Spondylitis | Q48012715 | ||
| HLA phenotypes and bullous cutaneous reactions to drugs. | Q54330000 | ||
| Risk of Stevens-Johnson syndrome and toxic epider mal necrolysis during first weeks of antiepileptic therapy: a case-control study | Q57244516 | ||
| Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia | Q74812275 | ||
| P433 | issue | 6982 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Stevens–Johnson syndrome | Q1053948 |
| medical genetics | Q1071953 | ||
| P304 | page(s) | 486 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Medical genetics: a marker for Stevens-Johnson syndrome | |
| P478 | volume | 428 |
| Q93590943 | Q93590943 |
| Q37658722 | "Omics" Technologies and the Immune System (a) , (b). |
| Q50761090 | 1st DIA Annual Japan Workshop for Pharmacogenomics in Tokyo. |
| Q28271411 | A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7 |
| Q90028488 | A Realistic Review of the Drug-Injury Relief System in Taiwan: Challenges, Lessons, and Achievements |
| Q64118851 | A Screening Test for in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events |
| Q37669205 | A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia |
| Q38147998 | A comparison of the efficacy and tolerability of oxcarbazepine oral suspension between infants and children with epilepsy: a retrospective chart review at a single medical center in Taiwan. |
| Q40817564 | A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering |
| Q64235675 | A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine |
| Q42966589 | A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury |
| Q34485108 | A marker for Stevens-Johnson syndrome ...: ethnicity matters |
| Q51186191 | A multiplex allele-specific real-time polymerase chain reaction assay for HLA-B*13:01 genotyping in four Chinese populations. |
| Q44811148 | A nested sequence-specific primer-polymerase chain reaction for the detection of HLA-B*15:02. |
| Q40051391 | A novel multiplex PCR assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions |
| Q44949302 | A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. |
| Q38085220 | A review of pharmacogenetics of adverse drug reactions in elderly people |
| Q36330968 | A roadmap for precision medicine in the epilepsies |
| Q58212027 | A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q48230093 | A study of HLA-B*15:02 in 9 different Chinese ethnics: Implications for carbamazepine related SJS/TEN. |
| Q50877130 | A success story in pharmacogenomics: genetic ID card for SJS/TEN. |
| Q38836848 | A web resource for mining HLA associations with adverse drug reactions: HLA-ADR |
| Q28545799 | ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs |
| Q34140322 | Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity |
| Q27008841 | Abacavir pharmacogenetics--from initial reports to standard of care |
| Q37803527 | Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles |
| Q38161477 | Activation of the TCR complex by small chemical compounds |
| Q37926255 | Adjunctive lacosamide in clinical practice: sodium blockade with a difference? |
| Q90328059 | Adjunctive levetiracetam in the treatment of Chinese and Japanese adults with generalized tonic-clonic seizures: A double-blind, randomized, placebo-controlled trial |
| Q93046453 | Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017 |
| Q38629246 | Adverse cutaneous drug eruptions: current understanding. |
| Q87840419 | Adverse drug effects and their clinical management: a personal view |
| Q57302751 | Adverse drug reactions and pharmacogenomics: recent advances |
| Q42072504 | Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study |
| Q47703247 | Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking |
| Q55899120 | Adverse effects of antiepileptic drugs |
| Q43144409 | Aggrenox (Asasantin retard)-induced Stevens-Johnson syndrome |
| Q55124503 | Allergy to chlorpromazine and valproic acid following carbamazepine hypersensitivity in a patient with an HLA-B*4601 allele. |
| Q90056765 | Allopurinol-induced severe cutaneous adverse reactions: A report of three cases with the HLA-B*58:01 allele who underwent lymphocyte activation test |
| Q40506118 | Allopurinol-induced severe hypersensitivity with acute renal failure |
| Q52719665 | An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. |
| Q48230747 | An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. |
| Q38026153 | Anticonvulsant hypersensitivity syndrome: an update |
| Q36952002 | Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care |
| Q89704272 | Antiepileptic drug-induced severe cutaneous adverse reactions and HLA alleles: A report of five cases with lymphocyte activation test |
| Q36513108 | Antiepileptic drugs 2012: recent advances and trends |
| Q47284170 | Applications of pharmacogenomics in regulatory science: a product life cycle review |
| Q34539515 | Applying genome-wide gene-based expression quantitative trait locus mapping to study population ancestry and pharmacogenetics |
| Q37695437 | Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. |
| Q38286229 | Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? |
| Q57697028 | Are health technology assessments of pharmacogenetic tests feasible? A case study ofCYP2D6testing in the treatment of breast cancer with tamoxifen |
| Q57244402 | Assessing and Explaining the Evidence on Harms of Medical Interventions |
| Q61807108 | Association Between HLA Genotype and Cutaneous Adverse Reactions to Antiepileptic Drugs Among Epilepsy Patients in Northwest China |
| Q41725845 | Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children |
| Q36526428 | Association between GABA(A) receptor subunit gene cluster and zolpidem-induced complex sleep behaviors in Han Chinese. |
| Q54094996 | Association between HLA gene polymorphism and cutaneous adverse reactions caused by antiepileptic drugs. |
| Q55324381 | Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. |
| Q51055927 | Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. |
| Q34629177 | Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese |
| Q42910293 | Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China |
| Q54364109 | Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. |
| Q54206970 | Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy. |
| Q47125857 | Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population |
| Q57557226 | Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population |
| Q43458952 | Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population |
| Q35453569 | Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis |
| Q45922634 | Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. |
| Q87393358 | Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population |
| Q46855666 | Association of Human Leukocyte Antigen Class 1 genes with Stevens Johnson Syndrome with severe ocular complications in an Indian population. |
| Q92380794 | Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients |
| Q46910307 | Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. |
| Q36740238 | Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population |
| Q34548358 | Association of increased frequencies of HLA-DPB1*05:01 with the presence of anti-Ro/SS-A and anti-La/SS-B antibodies in Japanese rheumatoid arthritis and systemic lupus erythematosus patients |
| Q50102015 | Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. |
| Q36625074 | Autoimmunity at the ocular surface: pathogenesis and regulation |
| Q42718095 | Avidity determines T-cell reactivity in abacavir hypersensitivity. |
| Q49612005 | Benefit of pre-emptive pharmacogenetic information on clinical outcome. |
| Q36253270 | Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015 |
| Q40575037 | Biomarkers for antiepileptic drug response |
| Q37946402 | Biomarkers in epilepsy: introduction |
| Q47928481 | Biomarkers of adverse drug reactions. |
| Q46620396 | Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study |
| Q34495636 | CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations |
| Q34598487 | Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. |
| Q34299895 | Carbamazepine-Induced Stevens-Johnson Syndrome Sparing the Skin Previously Affected by Herpes Zoster Infection in a Patient with Systemic Lupus Erythematosus: A Reverse Isotopic Phenomenon |
| Q57300409 | Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02 |
| Q90292010 | Carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a Filipino with positive HLA-B75 serotype |
| Q35233547 | Case report of two cases of fever, rash, and organ involvement during the treatment of leprosy |
| Q36341748 | Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy |
| Q41226295 | Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome |
| Q38766862 | Chronic Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: The Role of Systemic Immunomodulatory Therapy |
| Q52565859 | Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. |
| Q34345953 | Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. |
| Q24626941 | Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing |
| Q39013613 | Clinical and regulatory considerations in pharmacogenetic testing. |
| Q36441517 | Clinical application of high throughput molecular screening techniques for pharmacogenomics |
| Q34280685 | Clinical application of pharmacogenomics |
| Q38432845 | Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine. |
| Q36248267 | Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism |
| Q46975372 | Clinical perspectives in drug safety and adverse drug reactions |
| Q36029478 | Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing |
| Q24657536 | Clinical use of pharmacogenomic tests in 2009 |
| Q88009636 | Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality? |
| Q34138234 | Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles |
| Q42182914 | Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications-phenotypes and genetic predispositions |
| Q90151447 | Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome |
| Q34617803 | Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese |
| Q28552275 | Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions |
| Q36265940 | Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors |
| Q38182188 | Contributions of pharmacogenetics and transcriptomics to the understanding of the hypersensitivity drug reactions |
| Q90678926 | Controversies in drug allergy: Testing for delayed reactions |
| Q45216904 | Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand |
| Q51067041 | Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. |
| Q38671676 | Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? |
| Q49477079 | Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient. |
| Q90859692 | Cross-ethnicity tagging SNPs for HLA alleles associated with adverse drug reaction |
| Q40076524 | Current Japanese regulatory situations of pharmacogenomics in drug administration |
| Q47571365 | Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. |
| Q36174824 | Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics |
| Q36444480 | Current understanding of delayed anticonvulsant hypersensitivity reactions |
| Q38003494 | Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future |
| Q42132518 | Cutaneous drug hypersensitivity: immunological and genetic perspective |
| Q38120676 | Cutaneous drug reactions in children: an update. |
| Q36059568 | Cutaneous side effects of antiosteoporosis treatments |
| Q48517821 | Cytokine Polymorphism and HLA Genotyping in Patients with Temporal Lobe Epilepsy Related to Hippocampal Sclerosis. |
| Q37374228 | DNA variations in human and medical genetics: 25 years of my experience |
| Q92190152 | Dapsone- and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01 |
| Q91016148 | Defining Regional Differences in Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety? |
| Q82678361 | Defining the clinical role of pharmacogenetics in antiepileptic drug therapy |
| Q48903376 | Dermatology: the last 30 years--a rollercoaster ride. |
| Q50624617 | Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. |
| Q34663979 | Detection of ancestry informative HLA alleles confirms the admixed origins of Japanese population. |
| Q28585418 | Deubiquitinating enzyme USP33/VDU1 is required for Slit signaling in inhibiting breast cancer cell migration |
| Q64938049 | Developing pharmacogenetic screening methods for an emergent country: Vietnam. |
| Q45789317 | Development of a screening assay to evaluate the potential of drugs to cause immune-mediated hypersensitivity reactions |
| Q38178326 | Development of individualized medicine for epilepsy based on genetic information |
| Q47569828 | Diagnosing and managing patients with drug hypersensitivity |
| Q38600529 | Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis |
| Q64126362 | Different roads, same destination |
| Q41889353 | Digging up the human genome: current progress in deciphering adverse drug reactions. |
| Q64896816 | Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. |
| Q38552461 | Distribution of HLA haplotypes across Japanese Archipelago: similarity, difference and admixture |
| Q28749095 | Distributions of HLA-A and -B alleles and haplotypes in the Yi ethnic minority of Yunnan, China: relationship to other populations |
| Q35869663 | Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled |
| Q90249986 | Drug Hypersensitivity Reactions Documented in Electronic Health Records within a Large Health System |
| Q55564369 | Drug Induced Hypersensitivity and the HLA Complex. |
| Q37033603 | Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome |
| Q27679355 | Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire |
| Q89885623 | Drug hypersensitivity reactions in Asia: regional issues and challenges |
| Q34701492 | Drug hypersensitivity: pharmacogenetics and clinical syndromes |
| Q26739886 | Drug induced exfoliative dermatitis: state of the art |
| Q64241592 | Drug reaction with eosinophilia and systemic symptoms (DRESS) in children |
| Q30240144 | Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management |
| Q36412863 | Drug-Induced Liver Injury: Pattern Recognition and Future Directions |
| Q52346835 | Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. |
| Q39887958 | Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future |
| Q34708125 | Drug-induced skin, nail and hair disorders |
| Q46850588 | EMPACT syndrome. |
| Q47910482 | Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand |
| Q48006398 | Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine |
| Q34688725 | Emerging drugs for epilepsy |
| Q35988130 | Emerging strategies and applications of pharmacogenomics |
| Q38501423 | Eosinophilic Drug Allergy |
| Q34430859 | Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003. |
| Q34976470 | Epidemiology and risk factors for drug allergy |
| Q30249421 | Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia |
| Q37486720 | Epilepsy pharmacogenetics |
| Q42530312 | Ethnicity and adverse drug reactions |
| Q64126594 | Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy |
| Q26800980 | Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. |
| Q33926313 | Expectations, validity, and reality in pharmacogenetics |
| Q39261119 | External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy. |
| Q28648163 | Extracting research-quality phenotypes from electronic health records to support precision medicine |
| Q35294151 | Facilitating clinical implementation of pharmacogenomics |
| Q47594382 | Factors Affecting Drug-Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan |
| Q37056907 | Fatal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine-induced Stevens-Johnson syndrome |
| Q27692095 | Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. |
| Q89393378 | First step towards precision medicine for antithyroid drug-induced agranulocytosis |
| Q52660415 | Frank Stinchfield Award: Identification of the At-risk Genotype for Development of Pseudotumors Around Metal-on-metal THAs. |
| Q37806982 | From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics |
| Q83509385 | From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics |
| Q47155740 | Functional SNP allele discovery (fSNPd): an approach to find highly penetrant, environmental-triggered genotypes underlying complex human phenotypes |
| Q37765824 | Gene polymorphisms and their role in epilepsy treatment and prognosis |
| Q61639626 | Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations |
| Q90093046 | Genetic Predisposition to Anticonvulsant Hypersensitivity |
| Q40290352 | Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs |
| Q36028231 | Genetic aspects of immune-mediated adverse drug effects |
| Q37931275 | Genetic association studies in drug-induced liver injury |
| Q36555922 | Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications |
| Q89747408 | Genetic associations with clozapine-induced myocarditis in patients with schizophrenia |
| Q38095989 | Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. |
| Q35863499 | Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study |
| Q34508545 | Genetic factors in the predisposition to drug-induced hypersensitivity reactions |
| Q89155792 | Genetic markers of severe cutaneous adverse reactions |
| Q88120014 | Genetic predictors of Stevens-Johnson syndrome and toxic epidermal necrolysis induced by aromatic antiepileptic drugs among the Chinese Han population |
| Q37650570 | Genetic predisposition of life-threatening antiepileptic-induced skin reactions. |
| Q35307084 | Genetic predisposition to oxcarbazepine induced Stevens-Johnson syndrome |
| Q39487785 | Genetic risk factors for antiepileptic drug-induced hypersensitivity reactions in Israeli populations |
| Q24202114 | Genetic testing for prevention of severe drug-induced skin rash |
| Q47244043 | Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients |
| Q35649228 | Genetics of Interstitial Lung Disease: Vol de Nuit (Night Flight). |
| Q37845227 | Genetics of antipsychotic-induced side effects and agranulocytosis |
| Q64990277 | Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. |
| Q38207944 | Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review |
| Q28550088 | Genome-Wide Association Study in Immunocompetent Patients with Delayed Hypersensitivity to Sulfonamide Antimicrobials |
| Q49931634 | Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. |
| Q46732659 | Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions |
| Q28943413 | Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe |
| Q57302671 | Genome-wide association study of serious blistering skin rash caused by drugs |
| Q34257932 | Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions |
| Q35776279 | Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3 |
| Q46261017 | Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New "Fast-Second Winner" Strategy |
| Q91832588 | Genomic and clinical predictors of lacosamide response in refractory epilepsies |
| Q38114005 | Genomic medicine: a decade of successes, challenges, and opportunities |
| Q35252277 | Genomics and drug response |
| Q85280515 | Genotypes at rs2844682 and rs3909184 have no clinical value in identifying HLA-B*15:02 carriers |
| Q33582530 | Genotyping for severe drug hypersensitivity |
| Q37864479 | Global formulary review: how do we integrate pharmacogenomic information? |
| Q56503937 | Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q57063736 | HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians |
| Q47553722 | HLA Association with Drug-Induced Adverse Reactions. |
| Q37963995 | HLA alleles and drug hypersensitivity reactions |
| Q38134171 | HLA and disease: guilt by association |
| Q38037649 | HLA and pharmacogenetics of drug hypersensitivity. |
| Q33666857 | HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. |
| Q36508660 | HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. |
| Q38058271 | HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review |
| Q50502052 | HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors. |
| Q90263928 | HLA testing in the molecular diagnostic laboratory |
| Q37341208 | HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. |
| Q41704639 | HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients. |
| Q33788588 | HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions |
| Q34172669 | HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans |
| Q46859144 | HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. |
| Q45218456 | HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population |
| Q34566776 | HLA-B locus in Caucasian patients with carbamazepine hypersensitivity |
| Q46238859 | HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q36130790 | HLA-B*1301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China |
| Q51352373 | HLA-B*1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs. |
| Q35555607 | HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese |
| Q54393701 | HLA-B*1502 genotyping in two Chinese patients with phenytoin-induced Stevens-Johnson syndrome. |
| Q48145273 | HLA-B*1502 haplotype screening prior to carbamazepine administration in individuals of south-east Asian ancestry nears cost-effectiveness in preventing severe cutaneous adverse drug reactions. |
| Q40984481 | HLA-B*1502 in Iranian Children with Anticonvulsant Drugs-Induced Skin Reactions |
| Q30855868 | HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis |
| Q57273952 | HLA-B*38:02:01predicts carbimazole/methimazole-induced agranulocytosis |
| Q51199177 | HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions. |
| Q37514235 | HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects |
| Q24555784 | HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol |
| Q43053794 | HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis |
| Q44155333 | HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese |
| Q53434514 | HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. |
| Q52837404 | HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis. |
| Q30371340 | HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. |
| Q47826173 | HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. |
| Q38949927 | HLADR: a database system for enhancing the discovery of biomarkers for predicting human leukocyte antigen-mediated idiosyncratic adverse drug reactions. |
| Q47320133 | HLAs: Key regulators of T-cell-mediated drug hypersensitivity. |
| Q27335598 | Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome |
| Q62602871 | High-Throughput Sequencing in Respiratory, Critical Care, and Sleep Medicine Research. An Official American Thoracic Society Workshop Report |
| Q45806471 | Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population |
| Q37967102 | How epidemiology has contributed to a better understanding of skin disease |
| Q38917487 | Human Leukocyte Antigen Class I Genes Associated With Stevens-Johnson Syndrome and Severe Ocular Complications Following Use of Cold Medicine in a Brazilian Population |
| Q30238992 | Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity. |
| Q53361002 | Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. |
| Q38436048 | Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis |
| Q34579653 | Human leukocyte antigen typing using a knowledge base coupled with a high-throughput oligonucleotide probe array analysis |
| Q92436059 | Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond |
| Q39203656 | Human loci involved in drug biotransformation: worldwide genetic variation, population structure, and pharmacogenetic implications |
| Q37845911 | Hypersensitivity syndrome due to trichloroethylene exposure: a severe generalized skin reaction resembling drug-induced hypersensitivity syndrome |
| Q38056165 | Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients? |
| Q91174130 | Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing |
| Q92509274 | Identification of drug-specific public TCR driving severe cutaneous adverse reactions |
| Q30814834 | Identification of risk factors for carbamazepine-induced serious mucocutaneous adverse reactions: A case-control study using data from spontaneous adverse drug reaction reports. |
| Q36986507 | Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges |
| Q36770454 | Idiosyncratic adverse reactions to antiepileptic drugs |
| Q37510953 | Immune mediation of hypersensitivity adverse drug reactions: implications for therapy |
| Q36546268 | Immune response to xenobiotics in the skin: from contact sensitivity to drug allergy |
| Q27681301 | Immune self-reactivity triggered by drug-modified HLA-peptide repertoire |
| Q37486715 | Immunogenetics of drug-induced skin blistering disorders. Part II: synthesis |
| Q38766822 | Immunologic Mediators in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis |
| Q37786631 | Immunological aspects of nonimmediate reactions to beta-lactam antibiotics |
| Q34609440 | Immunological principles of T-cell-mediated adverse drug reactions in skin |
| Q38263760 | Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q24855057 | Immunotoxicogenomics: gene expression and immunotoxicology in the age of genomics |
| Q26787099 | Impact of New Genomic Technologies on Understanding Adverse Drug Reactions |
| Q38181565 | Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs |
| Q34436487 | Improved drug therapy: triangulating phenomics with genomics and metabolomics. |
| Q44050122 | Improved loop-mediated isothermal amplification for HLA-DRB1 genotyping using RecA and a restriction enzyme for enhanced amplification specificity. |
| Q34316771 | In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers |
| Q39909074 | In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper |
| Q37754599 | In vitro tests of T cell-mediated drug hypersensitivity. |
| Q91906258 | Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications |
| Q89040497 | Increased risk of strontium ranelate-related SJS/TEN is associated with HLA |
| Q37738258 | Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement |
| Q33847247 | Inferring genetic ancestry: opportunities, challenges, and implications |
| Q53782592 | Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. |
| Q33443448 | Influence of human leukocyte antigen (HLA) alleles and killer cell immunoglobulin-like receptors (KIR) types on heparin-induced thrombocytopenia (HIT). |
| Q57415259 | Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? |
| Q47960568 | Interethnic DNA methylation difference and its implications in pharmacoepigenetics |
| Q42672191 | Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments |
| Q46582583 | Interview: the National Institute of Neurological Diseases and Stroke/American Epilepsy Society benchmarks and research priorities for epilepsy research |
| Q46845991 | Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q42056265 | Investigation of Monnose-Binding Lectin gene Polymorphism in Patients with Erythema Multiforme, Stevens-Johnson Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Syndrome |
| Q84040825 | Is it time for drug sensitivity genetic screening? |
| Q46819272 | Ketamine continuous infusion for refractory status epilepticus in a patient with anticonvulsant hypersensitivity syndrome |
| Q43496241 | Lamotrigine-induced hypersensitivity syndrome in a Han Chinese patient with the HLA-B 5801 genotype |
| Q38644966 | Lessons from Genome-Wide Search for Disease-Related Genes with Special Reference to HLA-Disease Associations |
| Q80218672 | Long contiguous stretches of homozygosity in the human genome |
| Q35907547 | Looking back at genomic medicine in 2011. |
| Q37671321 | Lyell's Syndrome and Antimalarials: A Case Report and Clinical Review |
| Q57302639 | Mechanisms of Adverse Drug Reactions |
| Q90292421 | Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances |
| Q36089652 | Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. |
| Q36713347 | Molecular genetics of bipolar disorder and depression. |
| Q38107545 | Molecular insights from dysregulation of the thiazide-sensitive WNK/SPAK/NCC pathway in the kidney: Gordon syndrome and thiazide-induced hyponatraemia. |
| Q39247893 | More than 25 years of genetic studies of clozapine-induced agranulocytosis. |
| Q36436702 | Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo |
| Q38104383 | Multimodal neuroimaging: potential biomarkers for response to antiepileptic drugs? |
| Q53455058 | NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. |
| Q44357874 | NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice |
| Q47140255 | New Insights into Drug Reaction with Eosinophilia and Systemic Symptoms Pathophysiology |
| Q26800976 | New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity |
| Q43160887 | New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited |
| Q40589933 | Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome). |
| Q36439171 | Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions |
| Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
| Q36654226 | Occupational trichloroethylene exposure as a cause of idiosyncratic generalized skin disorders and accompanying hepatitis similar to drug hypersensitivities. |
| Q41941729 | Of race, ethnicity, and rash: the genetics of antiepileptic drug-induced skin reactions |
| Q88487480 | Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation |
| Q64993860 | Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report. |
| Q34605798 | Oxcarbazepine-induced Stevens-Johnson syndrome: a case report |
| Q40969931 | Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions |
| Q37876422 | Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring |
| Q37472027 | Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review |
| Q26784638 | Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back |
| Q49617664 | Patient ethnicity and the risk of immune-mediated adverse drug reactions. |
| Q83644418 | Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK |
| Q24339559 | Peptide-binding motifs and characteristics for HLA -B*13:01 molecule |
| Q38262011 | Personalized medicine approaches in epilepsy |
| Q57223243 | Personalized medicine for HLA-associated drug-hypersensitivity reactions |
| Q39190869 | Personalizing carbamazepine therapy |
| Q42157342 | PharmGKB summary: carbamazepine pathway |
| Q35168561 | PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. |
| Q58799157 | Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population |
| Q97883055 | Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions |
| Q38364825 | Pharmacogenetic considerations in the treatment of Parkinson's disease |
| Q37681573 | Pharmacogenetic considerations in the treatment of psychiatric disorders |
| Q37120841 | Pharmacogenetic information derived from analysis of HLA alleles |
| Q36243674 | Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery |
| Q42965039 | Pharmacogenetics |
| Q37772183 | Pharmacogenetics and human genetic polymorphisms |
| Q37892531 | Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs |
| Q40165805 | Pharmacogenetics at 50: genomic personalization comes of age. |
| Q35038056 | Pharmacogenetics in drug development |
| Q37657531 | Pharmacogenetics in reproductive and perinatal medicine |
| Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
| Q57302676 | Pharmacogenetics of Adverse Drug Reactions |
| Q38217627 | Pharmacogenetics of antiepileptic drug-induced hypersensitivity |
| Q35873680 | Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity |
| Q37845914 | Pharmacogenetics of cutaneous adverse drug reactions |
| Q34118186 | Pharmacogenetics of drug hypersensitivity |
| Q38139479 | Pharmacogenetics of mood disorders: what clinicians need to know |
| Q37763930 | Pharmacogenetics of toxic epidermal necrolysis. |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q47776901 | Pharmacogenetics: a general review on progress to date |
| Q38003392 | Pharmacogenetics: a reality or misplaced optimism? |
| Q52702236 | Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. |
| Q92712510 | Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation |
| Q92506521 | Pharmacogenomics |
| Q37946957 | Pharmacogenomics and epilepsy: the road ahead |
| Q37658586 | Pharmacogenomics and patient care: one size does not fit all. |
| Q34280025 | Pharmacogenomics and personalized medicine in neuropsychiatry |
| Q26765791 | Pharmacogenomics for personalized pain medicine |
| Q39359391 | Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries |
| Q89890370 | Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications |
| Q39084353 | Pharmacogenomics in epilepsy. |
| Q37967607 | Pharmacogenomics in neurology: current state and future steps |
| Q60046975 | Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit |
| Q27015820 | Pharmacogenomics of adverse drug reactions |
| Q38036150 | Pharmacogenomics of adverse drug reactions: implementing personalized medicine |
| Q34987138 | Pharmacogenomics of adverse drug reactions: practical applications and perspectives |
| Q30400366 | Pharmacogenomics of off-target adverse drug reactions |
| Q44807614 | Pharmacogenomics of severe cutaneous adverse reactions |
| Q34342305 | Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury |
| Q35135951 | Pharmacogenomics--how close/far are we to practising individualized medicine for children? |
| Q34976915 | Pharmacogenomics: the genetics of variable drug responses |
| Q39074126 | Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children |
| Q89361339 | Pharmacovigilance: Importance, concepts, and processes |
| Q58050282 | Pharmakogenetik |
| Q37874437 | Phenotype standardization for immune-mediated drug-induced skin injury. |
| Q40092387 | Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia |
| Q42432400 | Phenytoin Hypersensitivity: It's Time for Some Individuality |
| Q34348246 | Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients |
| Q57395688 | Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase |
| Q38814860 | Precision medicine for psychopharmacology: a general introduction |
| Q39103035 | Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology |
| Q38990891 | Precision medicine in genetic epilepsies: break of dawn? |
| Q47566249 | Precision medicine: does ethnicity information complement genotype-based prescribing decisions? |
| Q37541425 | Predicting HLA genotypes using unphased and flanking single-nucleotide polymorphisms in Han Chinese population |
| Q35784521 | Predicting disease using genomics |
| Q38161564 | Prediction of hypersensitivity to antibiotics: what factors need to be considered? |
| Q64285801 | Prevention and Diagnosis of Severe T-Cell-Mediated Adverse Drug Reactions: Are We There Yet? |
| Q39729427 | Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening |
| Q36180606 | Priorities and standards in pharmacogenetic research |
| Q28083100 | Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity |
| Q39642591 | Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability |
| Q50063459 | Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. |
| Q50595254 | Rapid and reliable screening of HLA-B*15:02 in four Chinese populations using single-tube multiplex real-time PCR assay. |
| Q39018771 | Rapid detection of HLA-A*31:01 allele in DNA and blood samples using loop-mediated isothermal amplification |
| Q33578364 | Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions |
| Q34131354 | Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice |
| Q55077637 | Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. |
| Q39000942 | Recent advances in epilepsy. |
| Q38931289 | Recent advances in the understanding of severe cutaneous adverse reactions |
| Q38457053 | Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms |
| Q41827577 | Recent progress of elucidating the mechanisms of drug hypersensitivity |
| Q29615658 | Regulating the p53 pathway: in vitro hypotheses, in vivo veritas |
| Q38074713 | Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments |
| Q36221786 | Reliability of statistical associations between genes and disease |
| Q57697208 | Removing barriers to a clinical pharmacogenetics service |
| Q30828357 | Replication and cross-phenotype study based upon schizophrenia GWASs data in the Japanese population: support for association of MHC region with psychosis. |
| Q38859829 | Requirements for comprehensive pharmacogenetic genotyping platforms |
| Q50143227 | Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. |
| Q40843603 | Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans |
| Q38391100 | Research priorities in epilepsy for the Asia-Oceanian region |
| Q35741951 | Risk factors for seizures and antiepileptic drug-associated adverse effects in high-grade glioma patients: A multicentre, retrospective study in Hong Kong |
| Q38396234 | Role of dermatology in pharmacogenomics: drug-induced skin injury. |
| Q38941642 | Role of pharmacogenetics in public health and clinical health care: a SWOT analysis |
| Q50115047 | SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. |
| Q34281872 | Safety and tolerability of antiepileptic drug treatment in children with epilepsy |
| Q92649408 | Screening HLA to Prevent Severe Drug Reactions-A Devil's Advocate Perspective |
| Q36241449 | Serious drug rashes in children |
| Q88160211 | Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management |
| Q28076600 | Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation |
| Q39291741 | Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice |
| Q41927200 | Severe Delayed Drug Reactions: Role of Genetics and Viral Infections. |
| Q34525532 | Severe cutaneous adverse drug reactions |
| Q55060097 | Severe cutaneous adverse reactions to drugs. |
| Q37992545 | Severe drug eruptions revisited |
| Q91841581 | Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions |
| Q40089040 | Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles |
| Q47109078 | Significance of functional disease-causal/susceptible variants identified by whole-genome analyses for the understanding of human diseases |
| Q37863710 | Skin manifestations of drug allergy |
| Q44438285 | Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects |
| Q37548990 | Spectrum of Cutaneous Adverse Reactions to Levetiracetam and Human Leukocyte Antigen Typing in North-Indian Patients |
| Q41992139 | Stabilization of Ultraviolet (UV)-stimulated Scaffold Protein A by Interaction with Ubiquitin-specific Peptidase 7 Is Essential for Transcription-coupled Nucleotide Excision Repair |
| Q53825089 | Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities. |
| Q28547203 | Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women |
| Q38611191 | Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update |
| Q41494133 | Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done |
| Q38164730 | Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective |
| Q40065957 | Stevens-Johnson syndrome and abuse of anabolic steroids. |
| Q41086444 | Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies |
| Q38629821 | Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction |
| Q44309626 | Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin |
| Q40311341 | Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases |
| Q37091877 | Stevens-Johnson syndrome: pathogenesis, diagnosis, and management |
| Q35280094 | Stevens-johnson syndrome: a case report |
| Q83673685 | Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients |
| Q35800006 | Success stories in genomic medicine from resource-limited countries |
| Q37436365 | Successful translation of pharmacogenetics into the clinic: the abacavir example |
| Q92362116 | Sutureless Amniotic Membrane Transplantation in a Pediatric Patient with Acute Toxic Epidermal Necrolysis |
| Q94398559 | Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome |
| Q38008573 | Systems biology tools for toxicology |
| Q26824166 | Systems pharmacology: network analysis to identify multiscale mechanisms of drug action |
| Q34971993 | T cell-mediated hypersensitivity reactions to drugs |
| Q38033651 | T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction |
| Q37780711 | T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. |
| Q45958696 | TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. |
| Q39275593 | TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis |
| Q47431684 | Tag SNPs for HLA-B alleles that are associated with drug response and disease risk in the Chinese Han population |
| Q34557668 | Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach. |
| Q36766056 | Testing for drug hypersensitivity syndromes |
| Q53251394 | The 2nd International Drug Hypersensitivity Meeting 18 - 21 April 2006, The University of Liverpool, Liverpool, UK. |
| Q87796110 | The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: focus on severe cutaneous adverse reactions |
| Q39123582 | The Application of Genomics in Diabetes: Barriers to Discovery and Implementation |
| Q41433207 | The Daniel K. Inouye College of Pharmacy Scripts: Precision Medicine Through the Use of Pharmacogenomics: Current Status and Barriers to Implementation |
| Q47717100 | The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct Vβ Receptors |
| Q36208161 | The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis |
| Q38166365 | The Epstein-Barr Virus EBNA1 Protein |
| Q37626751 | The HLA-A*31:01 allele: influence on carbamazepine treatment |
| Q53801531 | The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens-Johnson syndrome. |
| Q28080256 | The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity |
| Q33929926 | The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment |
| Q90749291 | The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity |
| Q52640903 | The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison to the USA FDA Label. |
| Q37626693 | The applications of pharmacogenetics to prescribing: what is currently practicable? |
| Q31122683 | The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population |
| Q50094090 | The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population. |
| Q36940885 | The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer |
| Q34225850 | The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q38200683 | The emerging era of pharmacogenomics: current successes, future potential, and challenges |
| Q51692060 | The future of psychiatric pharmacogenomics. |
| Q37859622 | The genetics of antiepileptic drug-induced skin reactions |
| Q92453423 | The genetics of bipolar disorder |
| Q38033613 | The management of toxic epidermal necrolysis |
| Q85236237 | The ophthalmologist's role in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Q40619738 | The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors |
| Q38577986 | The pharmacogenomics of epilepsy |
| Q58759292 | The risk factors of linezolid-induced lactic acidosis: A case report and review |
| Q34016198 | The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review |
| Q39427540 | The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions |
| Q81612489 | The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies |
| Q37292132 | The role of pharmacogenetics in treating central nervous system disorders |
| Q26851663 | The search for circulating epilepsy biomarkers |
| Q34473709 | The severe complication of Stevens-Johnson syndrome induced by long-term clozapine treatment in a male schizophrenia patient: a case report |
| Q38050483 | The structural basis of HLA-associated drug hypersensitivity syndromes |
| Q38305701 | The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression |
| Q36545002 | Theragenomic knowledge management for individualised safety of drugs, chemicals, pollutants and dietary ingredients |
| Q37925027 | Thiazide-induced hyponatraemia: epidemiology and clues to pathogenesis |
| Q42336625 | This issue at a glance |
| Q89330366 | Three clinical pearls in the treatment of patients with seizures and comorbid psychiatric disorders |
| Q42281124 | Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature |
| Q36494105 | Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. |
| Q26753044 | Tooth-brushing epilepsy: A case report and literature review |
| Q35661971 | Topical ophthalmic cyclosporine in the treatment of toxic epidermal necrolysis |
| Q30391847 | Towards precision medicine |
| Q33688133 | Towards the clinical implementation of pharmacogenetics in bipolar disorder. |
| Q26745232 | Toxic epidermal necrolysis |
| Q21202877 | Toxic epidermal necrolysis and Stevens-Johnson syndrome |
| Q35748816 | Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinoma |
| Q33587297 | Toxic epidermal necrolysis following treatment of pseudotumour cerebri: a case report |
| Q93604507 | Toxic epidermal necrolysis: an update |
| Q48085473 | Toxic epidermal necrolysis: the past, the guidelines and challenges for the future. |
| Q34013280 | Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications. |
| Q37119173 | Translating biomarkers to clinical practice |
| Q37046633 | Translational research: Basic science to health care. Way forward |
| Q37634345 | Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity |
| Q46963552 | Treatment of toxic epidermal necrolysis. Experience with 9 patients with consideration of intravenous immunoglobulin |
| Q38829886 | Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study |
| Q46429336 | USP7 small-molecule inhibitors interfere with ubiquitin binding |
| Q89737230 | USP7 stabilizes EZH2 and enhances cancer malignant progression |
| Q37663119 | Ubiquitin-specific peptidase 48 regulates Mdm2 protein levels independent of its deubiquitinase activity. |
| Q28072281 | Undercover: gene control by metabolites and metabolic enzymes |
| Q36134088 | Understanding and predicting binding between human leukocyte antigens (HLAs) and peptides by network analysis |
| Q38315875 | Understanding the complexity and malleability of T-cell recognition |
| Q36373816 | Update on pharmacogenetics in epilepsy: a brief review. |
| Q95840674 | Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care |
| Q91045698 | Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study |
| Q39941531 | Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage |
| Q38287616 | Using HLA typing to support patients with cancer. |
| Q36729620 | Various pharmacogenetic aspects of antiepileptic drug therapy: a review |
| Q28661627 | What Taiwan contributes to the world of allergy and clinical immunology? |
| Q43632749 | What does the growing prominence of Asia mean for pharmaceutical safety management? |
| Q46639562 | What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy? |
| Q42145368 | Who should support the costs of severe adverse drug reactions? |
| Q37826340 | Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs |
| Q54222263 | [Acute life-threatening drug reactions of the skin]. |
| Q87860038 | [Severe drug-induced skin reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis] |
| Q52641233 | [Severe skin reactions due to new medications]. |
| Q92982830 | eHealth as a Facilitator of Precision Medicine in Epilepsy |
Search more.